An observational study in Major Depression Moderate, Major Depression Severe and Major Depression With Comorbid Anxiety Symptoms, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Istanbul University - Cerrahpasa · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is one of 7 that started in 2026, is one of 8 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 28th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:
Gulhane Training and Research Hospital · Sites in Turkey
Ages 18–55 · Healthy volunteers
Medipol University · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 55+ · Healthy volunteers
Gulhane Training and Research Hospital · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 95 across the 24 interventional studies, 78 across the 8 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
Istanbul University - Cerrahpasa has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
11 of the studies in Depressive Disorder, Major with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT07534475Medipol UniversityVenous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT | 2026-11-30 |
| NCT07748091Istanbul University - CerrahpasaEEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07740694Istanbul University - CerrahpasaEEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07603804Istanbul University - CerrahpasaAccelerated iTBS for Major Depression | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant treatments, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement.
Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters.
Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, remain limited. In this regard, the present study aims to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for the development of personalized treatment approaches in the future.
Treatment-resistant depression (TRD) is defined as the failure to achieve an adequate clinical response to at least two antidepressant medications administered at appropriate doses and durations in individuals diagnosed with Major Depressive Disorder (MDD). TRD is associated with an increased risk of suicide, impaired social functioning, higher rates of hospitalization, and substantial economic burden. For this patient population, in whom conventional pharmacotherapy and psychotherapy often fail to provide sufficient benefit, electroconvulsive therapy (ECT) remains one of the most effective treatment options available. However, the mechanisms underlying the therapeutic effects of ECT have not been fully elucidated, and numerous biological, neurochemical, and structural hypotheses have been proposed.
Electroencephalography (EEG) is a non-invasive neurophysiological method capable of measuring the brain's electrical activity with high temporal resolution. Microstate analysis of EEG data focuses on brief periods of stable scalp topographies that are thought to represent transient states of large-scale neural networks. Each microstate is considered a temporary representation of a specific neural network, and parameters such as duration, occurrence, coverage, and transition probabilities provide valuable information about the brain's functional organization and dynamic stability. Although EEG-based studies investigating the effects of ECT on neuroplasticity, neurotransmitter systems, hippocampal volume, functional connectivity, and electrophysiological dynamics have gained increasing attention in recent years, research specifically focusing on microstate analysis remains limited. Existing studies are often characterized by small sample sizes, heterogeneity in treatment parameters, and potential confounding effects on microstate measures, highlighting the need for more comprehensive and controlled investigations in this field.
Accordingly, the present study aims to investigate the neurophysiological changes induced by ECT in individuals diagnosed with treatment-resistant depression through resting-state EEG microstate analysis. EEG recordings obtained before and after ECT will be compared to evaluate whether significant changes occur in microstate parameters, including duration, occurrence, coverage, and transition probabilities. Furthermore, the relationships between changes in microstate parameters and psychometric scale scores reflecting clinical improvement, together with other clinical variables, will be examined. Thus, not only the neurophysiological effects of ECT but also their associations with clinical outcomes will be comprehensively evaluated.
Another objective of the study is to investigate whether baseline EEG microstate characteristics may serve as potential biomarkers capable of predicting clinical response to ECT. By identifying neurophysiological indicators associated with favorable treatment outcomes, the study aims to advance predictive models for individualized treatment planning.
Through these aspects, the study seeks to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for future personalized treatment approaches.
Materials and Methods
The study will include voluntary patients between 18 and 60 years of age diagnosed with Major Depressive Disorder according to DSM-5 criteria, who have failed to respond to at least two antidepressant treatments and have been referred for ECT at the Department of Psychiatry, Cerrahpaşa Faculty of Medicine. Written informed consent will be obtained from all participants before enrollment.
The healthy control group will consist of age- and sex-matched volunteers aged 18 to 60 years who do not use any medication that may significantly influence EEG activity or inflammatory biomarkers and who do not have a current neurological or psychiatric disorder. Healthy controls will also provide written informed consent before participation. EEG recordings will be obtained once and will serve as reference data for normal brain activity.
ECT will be administered using the Thymatron System IV Integrated ECT Device under general anesthesia according to standard clinical protocols. Treatments will be delivered using bilateral electrode placement with brief-pulse square-wave stimulation. The duration of treatment, number of sessions, and stimulation parameters will be determined according to each patient's clinical condition.
Resting-state EEG recordings will be obtained from all participants within one week before the initiation of ECT and again during the 14 days up to 6 days and 8 weeks up to 6 days following completion of the ECT course. EEG data will be recorded using a computerized 19-channel EEG system with Ag-AgCl disc electrodes placed according to the international 10-20 system. The average of the A1 and A2 earlobe electrodes will be used as the reference. Recordings will be sampled at 512 Hz, with a high-pass filter of 0.30 Hz, a low-pass filter of 70 Hz, and an additional 50 Hz notch filter.
Participants will be instructed to remain relaxed, quiet, and motionless under supervision during the recording procedure. EEG acquisition will consist of 5 minutes with eyes open, followed by 5 minutes with eyes closed. Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing, before analysis.
Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension. Four canonical microstate classes (A, B, C, and D) will be identified. The following microstate parameters will be calculated for each participant and used in subsequent statistical analyses:
Duration: The average time (in milliseconds) during which a microstate remains stable once activated, reflecting the stability of the underlying neural network.
Occurrence: The average number of times a given microstate appears per second (Hz), reflecting the activation tendency of the associated neural network.
Coverage: The percentage of total recording time occupied by a specific microstate, indicating the relative contribution of that neural network over time.
Transition Probability (TP): The probability of transitioning from one microstate to another. For example, the transition probability from microstate A to microstate B is calculated as the number of A-to-B transitions divided by the total number of transitions from A to all other microstate classes. This parameter provides insight into the sequential activation dynamics of neural networks.
Before ECT initiation and 2 and 8 weeks after the cessation of ECT sessions, participants will complete a sociodemographic data form, the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Beck Scale for Suicide Ideation (BSSI), Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression Scale (CGI), the Mini-Mental State Examination (MMSE), and the Center for Epidemiologic Studies-Depression (CES-D). These assessments will be repeated before the post-treatment EEG recording.
Treatment response on the BDI will be defined as a reduction of at least 50% from baseline scores, while remission will be defined as a total score of 10 or lower. Similarly, for the HAM-D-17, treatment response will be defined as a reduction of at least 50% from baseline scores, and remission will be defined as a total score below 7.
Peripheral venous blood samples will be collected from all patients at three time points: within one week before the initiation of ECT and during the second and eighth weeks following completion of the ECT treatment course. All blood samples will be obtained in the morning after an overnight fast.
A total of 10 mL of venous blood will be collected from each participant between 7.30-9.30 am in the fasting state. Blood samples will be divided into EDTA-containing tubes for complete blood count analyses and serum separator tubes for biochemical and inflammatory biomarker measurements.
Following collection, serum samples will be centrifuged and aliquoted according to standard laboratory procedures. All serum specimens will be stored at -80°C until biochemical analyses are performed.
Study Timeline
Ethics committee approval is planned during the first month of the study. Participant recruitment will take place between months 2 and 6, followed by data analysis and completion of the study between months 6 and 8.
Statistical Analysis
Sample size estimation will be performed using G*Power v3.1.9 (Faul et al., 2009), assuming an effect size of 0.70 and a statistical power (1-β) of 0.85. The power analysis indicated that a minimum of 31 patients and 31 healthy controls are required. The sample size calculation was based on clinical treatment response as the primary outcome measure.
EEG data will be analyzed using EEGLAB running on MATLAB. Statistical analyses will be conducted using SPSS version 27. Continuous variables will be analyzed using one-way analysis of variance (ANOVA) when comparing more than two groups. Appropriate post-hoc analyses will follow significant findings. Categorical variables will be analyzed using chi-square tests. Relationships between continuous variables will be evaluated using Pearson correlation coefficients. Independent group comparisons will be performed using the Paired Samples t-test. For within-subject comparisons of pre- and post-treatment measures, paired-samples t-tests or non-parametric equivalents will be employed as appropriate.
Patients between 18 and 60 years of age diagnosed with Treatment-Resistant Major Depressive Disorder and suggested ECT sessions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Group
Healthy Control Group:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Electroconvulsive Therapy
The healthy control group will consist of age- and sex-matched volunteers between 18 and 60 years of age who do not use any medication that may significantly influence EEG activity or inflammatory biomarkers, and who do not have a current neurological or psychiatric disorder. Healthy controls will also provide written informed consent before participation. EEG recordings will be obtained once and will serve as reference data for normal brain activity.
ECT will be administered using the Thymatron System IV Integrated ECT Device under general anesthesia, in accordance with standard clinical protocols. Treatments will be delivered using bilateral electrode placement with brief-pulse square-wave stimulation, and if side effects are seen, right unilateral electrode placement will be applied. The duration of treatment, number of sessions, and stimulation parameters will be determined according to each patient's clinical condition.
Clinical Response and Remission Assessed by the Montgomery-Åsberg Depression Rating Scale
Before ECT initiation and 2 and 8 weeks after the cessation of ECT sessions, depressive symptom severity will be assessed using the Montgomery-Åsberg Depression Rating Scale. Montgomery-Åsberg Depression Rating Scale total score ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. Change in total score from baseline will be assessed following electroconvulsive therapy (ECT).Clinical response will be defined as a ≥50% reduction in MADRS total score from baseline. Remission will be defined as a MADRS total score ≤7.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Hamilton Depression Rating Scale
Before ECT initiation and 2 and 8 weeks after the cessation of ECT sessions, depressive symptom severity will be assessed using the Hamilton Depression Rating Scale. The total score of scale ranges from 0 to 52, with higher scores indicating greater severity of depressive symptoms. Change in Hamilton Depression Rating Scale total score from baseline will be assessed following electroconvulsive therapy (ECT).Clinical response will be defined as a ≥50% reduction in total score from baseline. Remission will be defined as a total score ≤7.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
EEG Microstate Duration
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording. EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed. Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing. Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension. Four canonical microstate classes (A, B, C, and D) will be identified. For each microstate class, duration will be calculated as the mean time for which the microstate remains stable following its onset and will be reported in milliseconds (ms).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
EEG Microstate Occurrence
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording. EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed. Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing. Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension. Four canonical microstate classes (A, B, C, and D) will be identified. For each microstate class, occurrence will be calculated as the mean number of times the microstate occurs per second and will be reported in Hertz (Hz).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
EEG Microstate Coverage
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording. EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed. Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing. Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension. Four canonical microstate classes (A, B, C, and D) will be identified. For each microstate class, coverage will be calculated as the percentage of the total EEG recording time occupied by that microstate class and will be reported as a percentage (%).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
EEG Microstate Transition Probability
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording. EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed. Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing. Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension. Four canonical microstate classes (A, B, C, and D) will be identified. For each pair of microstate classes, transition probability will be calculated as the proportion of transitions from a given microstate class to a specific subsequent microstate class relative to all transitions originating from that microstate class. Transition probability will be reported as a proportion ranging from 0 to 1.
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
Correlation between baseline neuroinflammatory biomarkers and treatment response
Correlation coefficients between baseline concentrations of neuroinflammatory biomarkers and change in Hamilton Depression Rating Scale scores following ECT will be calculated.
Time frame: These assessments will be repeated at three time points: within 1 week before ECT starts, 14+6 days and 8 weeks + 6 days after ECT cessation.
Correlation between baseline neuroinflammatory biomarkers and treatment response
Correlation coefficients between baseline concentrations of neuroinflammatory biomarkers and change in Montgomery-Asberg Depression Rating Scale scores following ECT will be calculated.
Time frame: These assessments will be repeated at three time points: within 1 week before ECT starts, 14+6 days and 8 weeks + 6 days after ECT cessation.
Correlation between changes in neuroinflammatory biomarkers and EEG microstate parameters
Correlation coefficients between changes in neuroinflammatory biomarker concentrations and changes in EEG microstate parameters (duration, occurrence, coverage, and transition probabilities) following ECT will be calculated.
Time frame: These assessments will be repeated at three time points: within one week before ECT starts, 14+6 days and 8 weeks + 6 days after ECT cessation.
Inflammatory indices derived from complete blood count
Neutrophil-to-Lymphocyte Ratio (NLR) will be calculated from complete blood count parameters and expressed as ratios.
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
Inflammatory indices derived from complete blood count
Platelet-to-Lymphocyte Ratio (PLR) will be calculated from complete blood count parameters and expressed as ratios.
Time frame: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Inflammatory indices derived from complete blood count
Monocyte-to-Lymphocyte Ratio (MLR) will be calculated from complete blood count parameters and expressed as ratios.
Time frame: These assessments will be repeated within 1 week before ECT starts, at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Clinical Global Impression- Severity
Overall illness severity will be assessed using the Clinical Global Impression-Severity scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The scale is a 7-point clinician-rated scale ranging from 3 to 18, with higher scores indicating greater overall illness severity. Changes in CGI-S the scale scores from baseline will be evaluated following ECT.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Beck Scale for Suicidal Ideation
Suicidal ideation will be assessed using the Beck Scale for Suicide Ideation before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The Beck Scale for Suicide Ideation consists of 19 scored items, with a total score ranging from 0 to 38; higher scores indicate greater severity of suicidal ideation. A ≥50% reduction in the Beck Scale for Suicide Ideation total score from baseline will be used to define treatment response, and a total score ≤6 will be used to define remission.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Hamilton Anxiety Scale
Anxiety symptoms will be assessed using the Hamilton Anxiety Rating Scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The Hamilton Anxiety Rating Scale consists of 14 items, with a total score ranging from 0 to 56; higher scores indicate greater severity of anxiety symptoms. A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤7 will be used to define remission.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Beck Anxiety Scale
Anxiety symptoms will be assessed using the Beck Anxiety Inventory before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The Beck Anxiety Inventory consists of 21 items, with a total score ranging from 0 to 63; higher scores indicate greater severity of anxiety symptoms. A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤10 will be used to define remission.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Beck Depression Inventory
Depressive symptoms will be assessed using the Beck Depression Inventory before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The Beck Depression Inventory consists of 21 items, with a total score ranging from 0 to 63; higher scores indicate greater severity of depressive symptoms. A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤9 will be used to define remission.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Response Assessed by Center for Epidemiologic Studies Depression Scale
Depressive symptoms will be assessed using the Center for Epidemiologic Studies Depression Scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The scale consists of 20 items, with a total score ranging from 0 to 60; higher scores indicate greater severity of depressive symptoms. Changes in the total scores from baseline will be evaluated following ECT.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
Concentration of peripheral neuroinflammatory biomarkers
Concentrations of soluble glycoprotein 130 (sgp130) and soluble interleukin-6 receptor (sIL-6R) will be measured from peripheral blood samples using ELISA assays. (ng/ml).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
Concentration of peripheral neuroinflammatory biomarkers
Concentrations of IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α, interferon gamma-induced protein-10 (IP-10), will be measured from peripheral blood samples using ELISA assays ( pg/mL).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
Concentration of peripheral neuroinflammatory biomarkers
Concentrations of C-reactive protein (CRP) will be measured from peripheral blood samples using ELISA assays ( mg/L).
Time frame: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
Clinical Cognitive Assessment
Cognitive function will be assessed using the Mini-Mental State Examination before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions. The scale is a clinician-administered cognitive assessment with a total score ranging from 0 to 30, with higher scores indicating better cognitive function. Changes in the total scores from baseline will be evaluated following ECT.
Time frame: These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 11 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →